A numerical and analytical study of two holes doped into the 2D t--J model

Exact diagonalization numerical results are presented for a 32-site square cluster, with two holes propagating in an antiferromagnetic background described by the t-J model. We characterize the wave function of the lowest energy bound state found in this calculation, which has d_{x^2-y^2} symmetry. Analytical work is presented, based on a Lang-Firsov-type canonical transformation derived quasiparticle Hamiltonian, that accurately agrees with numerically determined values for the electron momentum distribution function and the pair correlation function. We interpret this agreement as strong support for the validity of this description of the hole quasiparticles.Comment: 3 pages, REVTeX, to appear in the proceedings of the Fifth International Conference on Spectroscopies in Novel Superconductors, September 14-18, 1997, Cape Cod, Massachusett

Dynamics of young stellar clusters as planet-forming environments

Most stars and thus most planetary systems do not form in isolation. The larger star-forming environment affects protoplanetary disks in multiple ways: Gravitational interactions with other stars truncate disks and alter the architectures of exoplanet systems; external irradiation from nearby high-mass stars truncates disks and shortens their lifetimes; and the remaining gas and dust in the environment affect dynamical evolution (if removed by feedback processes) and provide some shielding for disks from external irradiation. The dynamical evolution of the region regulates when and how long various feedback mechanisms impact protoplanetary disks. Density is a key parameter that regulates the intensity and duration of UV irradiation and the frequency of dynamical encounters. The evolution of larger star-forming complexes may also play an important role by mixing populations. Observations suggest that clusters are not a single-age population but multiple populations with small age differences, which may be key to resolving several timescale issues (i.e., proplyd lifetimes, enrichment). In this review, we consider stellar clusters as the ecosystems in which most stars and therefore most planets form. We review recent observational and theoretical results and highlight upcoming contributions from facilities expected to begin observations in the next 5 years. Looking further ahead, we argue that the next frontier is large-scale surveys of low-mass stars in more distant high-mass star-forming regions. The future of ecosystem studies is bright as faint low-mass stars in more distant high-mass star-forming regions will be routinely observable in the era of extremely large telescopes

A tale of two clusters: dynamical history determines disc survival in Tr14 and Tr16 in the Carina Nebula

Understanding how the birthplace of stars affects planet-forming discs is important for a comprehensive theory of planet formation. Most stars are born in dense star-forming regions where the external influence of other stars, particularly the most massive stars, will affect the survival and enrichment of their planet-forming discs. Simulations suggest that stellar dynamics play a central role in regulating how external feedback affects discs, but comparing models to observations requires an estimate of the initial stellar density in star-forming regions. Structural analyses constrain the amount of dynamical evolution a star-forming region has experienced; regions that maintain substructure and do not show mass segregation are likely dynamically young, and therefore close to their birth density. In this paper, we present a structural analysis of two clusters in the Carina Nebula, Tr14 and Tr16. We show that neither cluster shows evidence for mass segregation or a centrally concentrated morphology, suggesting that both regions are dynamically young. This allows us to compare to simulations from Nicholson et al., who predict disc survival rates in star-forming regions of different initial densities. The surviving disc fractions in Tr14 and Tr16 are consistent with their predictions (both are ∼10 per cent), supporting a growing body of evidence that the star-forming environment plays an important role in the survival and enrichment of protoplanetary discs

Resveratrol is a promising agent for colorectal cancer prevention and treatment: Focus on molecular mechanisms

Colorectal cancer (CRC) is the third most common cancer and one of the main causes of cancer death entire the world. Environmental, dietary, and lifestyle factors including red meat consumption, cigarette smoking, alcohol intake and family history are the most important risk factors of CRC. Multiple pathways including inflammation, oxidative stress, and apoptosis are involved in its incidence and progression. Resveratrol, a polyphenolic compound, has different pharmacologic functions including anti-inflammation, cancer prevention, lipid-lowering effect, and hypoglycemic effect. Many studies have proved that resveratrol might also represent a chemo preventive effect on CRC. Thus, the aim of the current review is to depict the role of resveratrol in treatment of CRC in a molecular manner. © 2019 The Author(s)

Actors, actions, and initiative in normative system specification

The logic of norms, called deontic logic, has been used to specify normative constraints for information systems. For example, one can specify in deontic logic the constraints that a book borrowed from a library should be returned within three weeks, and that if it is not returned, the library should send a reminder. Thus, the notion of obligation to perform an action arises naturally in system specification. Intuitively, deontic logic presupposes the concept of anactor who undertakes actions and is responsible for fulfilling obligations. However, the concept of an actor has not been formalized until now in deontic logic. We present a formalization in dynamic logic, which allows us to express the actor who initiates actions or choices. This is then combined with a formalization, presented earlier, of deontic logic in dynamic logic, which allows us to specify obligations, permissions, and prohibitions to perform an action. The addition of actors allows us to expresswho has the responsibility to perform an action. In addition to the application of the concept of an actor in deontic logic, we discuss two other applications of actors. First, we show how to generalize an approach taken up by De Nicola and Hennessy, who eliminate from CCS in favor of internal and external choice. We show that our generalization allows a more accurate specification of system behavior than is possible without it. Second, we show that actors can be used to resolve a long-standing paradox of deontic logic, called the paradox of free-choice permission. Towards the end of the paper, we discuss whether the concept of an actor can be combined with that of an object to formalize the concept of active objects

Phytomelatonin: Assisting plants to survive and thrive

This review summarizes the advances that have been made in terms of the identified functions of melatonin in plants. Melatonin is an endogenously-produced molecule in all plant species that have been investigated. Its concentration in plant organs varies in different tissues, e.g., roots versus leaves, and with their developmental stage. As in animals, the pathway of melatonin synthesis in plants utilizes tryptophan as an essential precursor molecule. Melatonin synthesis is inducible in plants when they are exposed to abiotic stresses (extremes of temperature, toxins, increased soil salinity, drought, etc.) as well as to biotic stresses (fungal infection). Melatonin aids plants in terms of root growth, leaf morphology, chlorophyll preservation and fruit development. There is also evidence that exogenously-applied melatonin improves seed germination, plant growth and crop yield and its application to plant products post-harvest shows that melatonin advances fruit ripening and may improve food quality. Since melatonin was only discovered in plants two decades ago, there is still a great deal to learn about the functional significance of melatonin in plants. It is the hope of the authors that the current review will serve as a stimulus for scientists to join the endeavor of clarifying the function of this phylogenetically-ancient molecule in plants and particularly in reference to the mechanisms by which melatonin mediates its multiple actions

Melatonin is a potential inhibitor of ovarian cancer: Molecular aspects

Ovarian cancer is one of the most common causes of morbidity related to gynecologic malignancies. Possible risk factors are including hereditary ovarian cancer, obesity, diabetes mellitus, alcohol consumption, aging, and smoking. Various molecular signaling pathways including inflammation, oxidative stress, apoptosis and angiogenesis are involved in this progression of ovarian cancer. Standard treatments for recently diagnosed patients are Surgery and chemotherapy such as co-treatment with other drugs such that the exploitation of neoadjuvant chemotherapy is expanding. Melatonin (N-acetyl-5-methoxy-tryptamine), an endogenous agent secreted from the pineal gland, has anti-carcinogenic features, such as regulation of estradiol production, cell cycle modulation, stimulation of apoptosis as well as anti-angiogenetic properties, anti-inflammatory activities, significant antioxidant effects and modulation of various immune system cells and cytokines. Multiple studies have shown the significant beneficial roles of melatonin in various types of cancers including ovarian cancer. This paper aims to shed light on the roles of melatonin in ovarian cancer treatment from the standpoint of the molecular aspects. © 2019 The Author(s)

Correction: The Effects of Melatonin Supplementation on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

his systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to clarify the effect of melatonin supplementation on glycemic control. Databases including PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials were searched until July 30th, 2018. Two reviewers independently assessed study eligibility, extracted data, and evaluated the risk of bias for included trials. Heterogeneity among included studies was assessed using Cochran’s Q test and I-square (I2) statistic. Data were pooled using random-effect models and mean difference (MD) was considered as the overall effect size. Twelve trials out of 292 selected reports were identified eligible to be included in current meta-analysis. The pooled findings indicated that melatonin supplementation significantly reduced fasting glucose (MD=–6.34; 95% CI, –12.28, –0.40; p=0.04; I2: 65.0) and increased the quantitative insulin sensitivity check index (QUICKI) (MD=0.01; 95% CI, 0.00, 0.02; p=0.01; I2: 0.0). However, melatonin administration did not significantly influence insulin levels (MD=–1.03; 95% CI, –3.82, 1.77; p=0.47; I2: 0.53), homeostasis model assessment of insulin resistance (HOMA-IR) (MD=–0.34; 95% CI, –1.25, 0.58; p=0.37; I2: 0.37) or HbA1c levels (MD=–0.22; 95% CI, –0.47, 0.03; p=0.08; I2: 0.0). In summary, the current meta-analysis showed a promising effect of melatonin supplementation on glycemic control through reducing fasting glucose and increasing QUICKI, yet additional prospective studies are recommended, using higher supplementation doses and longer intervention period, to confirm the impact of melatonin on insulin levels, HOMA-IR and HbA1c. Key words: melatonin - glycemic control - insulin resistance - meta-analysi

Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial

Background & aims: Melatonin may benefit diabetic people with coronary heart disease (CHD) through its beneficial effects on biomarkers of oxidative stress and cardio-metabolic risk. This investigation evaluated the effects of melatonin administration on metabolic status in diabetic patients with CHD. Methods: This randomized, double-blind, placebo-controlled trial was conducted and involved 60 diabetic patients with CHD. Subjects were randomly allocated into two groups to receive either 10 mg melatonin (2 melatonin capsules, 5 mg each) (n = 30) or placebo (n = 30) once a day for 12 weeks. Results: Compared with the placebo, melatonin supplementation resulted in significant increases in plasma glutathione (GSH) (+64.7 ± 105.7 vs. �11.1 ± 137.6 μmol/L, P = 0.02) and nitric oxide (NO) (+0.9 ± 4.7 vs. �3.3 ± 9.6 μmol/L, P = 0.03), and significant decreases in malondialdehyde (MDA) (�0.2 ± 0.3 vs. +0.1 ± 0.5 μmol/L, P = 0.007), protein carbonyl (PCO) (�0.12 ± 0.08 vs. +0.03 ± 0.07 mmol/mg protein, P < 0.001) and serum high sensitivity C-reactive protein (hs-CRP) levels (�1463.3 ± 2153.8 vs. +122.9 ± 1230.4 ng/mL, P = 0.001). In addition, taking melatonin, compared with the placebo, significantly reduced fasting plasma glucose (�29.4 ± 49.0 vs. �5.5 ± 32.4 mg/dL, P = 0.03), serum insulin concentrations (�2.2 ± 4.1 vs. +0.7 ± 4.2 μIU/mL, P = 0.008), homeostasis model of assessment-estimated insulin resistance (�1.0 ± 2.2 vs. +0.01 ± 1.6, P = 0.04), total-/HDL-cholesterol ratio (�0.18 ± 0.38 vs. +0.03 ± 0.35, P = 0.02) and systolic (�4.3 ± 9.6 vs. +1.0 ± 7.5 mmHg, P = 0.01) and diastolic blood pressure (�2.8 ± 7.3 vs. +0.1 ± 3.6 mmHg, P = 0.04). Melatonin treatment also significantly increased quantitative insulin sensitivity check index (+0.006 ± 0.01 vs. �0.004 ± 0.01, P = 0.01) and serum HDL-cholesterol (+2.6 ± 5.5 vs. �0.01 ± 4.4 mg/dL, P = 0.04). Supplementation with melatonin had no significant effect on other metabolic parameters. Conclusions: Overall, melatonin intake for 12 weeks to diabetic patients with CHD had beneficial effects on plasma GSH, NO, MDA, PCO, serum hs-CRP levels, glycemic control, HDL-cholesterol, total-/HDL-cholesterol ratio, blood pressures and parameters of mental health. Registered under ClinicalTrials.gov Identifier no. http://www.irct.ir: IRCT2017051333941N1. © 2017 Elsevier Ltd and European Society for Clinical Nutrition and Metabolis

Melatonin and non-small cell lung cancer: New insights into signaling pathways

Non-small-cell lung cancer (NSCLC) is a type of malignancy with progressive metastasis having poor prognosis and lowered survival resulting from late diagnosis. The therapeutic approaches for the treatment of this incurable cancer are chemo- and radiotherapy. Since current treatments are insufficient and because of drug-induced undesirable side effects and toxicities, alternate treatments are necessary and critical. The role of melatonin, produced in and released from the pineal gland, has been documented as a potential therapy for NSCLC. Melatonin prevents tumor metastasis via inducing apoptosis processes and restraining the autonomous cell proliferation. Moreover, melatonin inhibits the progression of tumors due to its oncostatic, pro-oxidant and anti-inflammatory effects. As a result, the combined treatment with melatonin and chemotherapy may have a synergistic effect, as with some other tumors, leading to a prolonged survival and improved quality of life in patients with NSCLC. This review summarizes the available data, based on the molecular mechanisms and related signaling pathways, to show how melatonin and its supplementation function in NSCLC. © 2019 The Author(s)